Inhibition of tumor cell macropinocytosis driver DHODH reverses immunosuppression and overcomes anti-PD1 resistance
Authors:
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82388201)
- China Postdoctoral Science Foundation (2022M710449)
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2024-I2M-ZD-005)
- Chinese Academy of Medical Sciences Initiative for Innovative Medicine (2021-I2M-1-017)
- National Postdoctoral Program for Innovative Talents (BX2021046)
This publication has 61 references indexed in Scilit:
- Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responsesCancer Cell, 2022
- MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancerCancer Cell, 2022
- Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistanceCancer Cell, 2022
- Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancerCancer Letters, 2021
- Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic EfficacyCancer Cell, 2019
- Organelle Specific O-Glycosylation Drives MMP14 Activation, Tumor Growth, and MetastasisCancer Cell, 2017
- Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in MelanomaCancer Cell, 2016
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer ProgressionCell, 2015
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- DUP 785 (NSC 368390): Schedule-dependency of growth-inhibitory and antipyrimidine effectsBiochemical Pharmacology, 1988